Abstract: Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor nilotinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer. In some embodiments, the pharmaceutical compositions can be administered without regard to food consumption. In other embodiments, the pharmaceutical compositions can be administered at a significantly lower dose as compared to a commercially available immediate-release nilotinib formulation, while providing a comparable therapeutic effect.

Abstract: A method of preparing rumen-protected polyunsaturated fatty acids (RuPUFAs) for use in ruminant feeds by inducing the Maillard reaction between a reducing carbohydrate source and de-oiled lecithin in the presence of a PUFA under reduced pressure conditions is disclosed. Products made by the process, as well as methods for enhancing performance, assisting the induction of pregnancy, alleviating inflammation, modulating fetus growth, improving immune system function, and modulation of the fatty acid composition of meat and milk of ruminant animals are also disclosed.

Abstract: In one aspect, the invention provides methods of increasing immune response by administering postcellular signaling factors produced by cells exposed to a stress condition. In one aspect, the invention provides methods of increasing immune response by administering in combination (a) a Stimulator of Interferon Genes (STING) agonist and (b) a purinergic receptor agonist. The increase in immune response may be used, for example, for treatment of infection or cancer. The invention also provides screening assays for identification of compounds that induce production of postcellular signaling factors which are also immunostimulatory agents. The invention further provides methods for identifying postcellular signaling factors with immunostimulatory activity. In another aspect, the invention provides methods of decreasing immune response by administering to a cell, tissue or subject a purinergic receptor antagonist alone or in combination with a Stimulator of Interferon Genes (STING) antagonist.

Abstract: Described are transdermal drug delivery compositions comprising amphetamine, methods of making transdermal drug delivery compositions comprising amphetamine, and therapeutic methods of using them. In specific embodiments, the compositions are free of components with moieties that are reactive with amphetamine. In specific embodiments, the compositions are manufactured using solvents free of components with moieties that are reactive with amphetamine. Therapeutic methods using the compositions also are described.

Abstract: The present invention relates to a photoprotective composition for topical use comprising, in a cosmetically acceptable medium, at least one dibenzoylmethane derivative compound, at least one merocyanine compound and at least one compound capable of accepting the triplet excited level energy of said dibenzoylmethane derivative compound(s). The invention also relates to the use of at least one compound capable of accepting the triplet excited level energy of said dibenzoylmethane derivative compound(s), for photostabilizing with respect to UV radiation a composition comprising at least one dibenzoylmethane derivative compound and at least one merocyanine compound.

Abstract: The present invention relates to a cosmetic process for treating keratin fibres, preferably human keratin fibres such as the hair, in particular for conditioning keratin fibres, using a combination of at least two different compositions, the first composition comprising one or more oxyalkylenated and preferably oxyethylenated silicones and one or more cationic surfactants and the second composition comprising water and one or more amino silicones. The invention also relates to a kit comprising the two compositions. Finally, the invention relates to a ready-to-use cosmetic composition for treating keratin fibres.

Abstract: Methods for inhibiting tissue ossification or calcification in a subject, comprising administering a therapeutically effective amount of BMP I inhibitor-loaded microparticles to a subject in need thereof, wherein the administration provides local and sustained release of the BMP I inhibitor thereby inhibiting tissue ossification or calcification.

Abstract: The present invention relates to oral ready to use liquid pharmaceutical compositions of eslicarbazepine. It also relates to the processes for the preparation of said liquid compositions. The present invention provides liquid compositions of eslicarbazepine with desired technical attributes such as release profile, viscosity, pH, stability, and acceptable organoleptic properties. The prepared compositions are useful in patients having difficulties in swallowing tablets and provide the physician with providing a more convenient and less cumbersome posology.

Abstract: A GRAS list chemical composition (containing only GRAS list approved ingredients) including a water-based bowel cleansing solution (either in concentrate form or diluted form) to clean a gastrointestinal (GI) tract before and/or during performance of an endoscopy procedure such as a colonoscopy, enteroscopy, upper gastrointestinal endoscopy, and small bowel capsule endoscopy, for example. The GRAS list bowel cleansing chemical composition includes at least one of a chemical composition as a liquid, tablet or powder concentrate that can be added to sterile water or other solution by the end-user to make the chemical composition solution; and a pre-mixed chemical composition solution diluted in up to 1000 ml of sterile water.

Abstract: Provided here are new ophthalmologically suitable pharmaceutical compositions comprising an effective amount of a moxifloxacin compound and an effective amount of a triamcinolone compound. In aspects, the compositions are stable suspensions, which maintain physical stability and chemical stability for extended periods of time (e.g., exhibiting no sustained flocculation, coagulation, or clumping after several months of storage under typical storage conditions). In aspects, the compositions are suspensions that include a suspension component comprising one or more suspension agents. In aspects, the suspension component includes an ionic suspension agent. In aspects, the composition also or alternatively comprises a non-ionic surfactant, non-ionic suspension agent, or both, or an agent that provides both functions. In aspects, such compositions further comprise an effective amount of a chelating agent/component. Further described are related compositions and methods of making and using such compositions, e.g.

Abstract: A hydrogel delivery composition and method, including degradable microcapsules suspended in a degradable thermo-responsive hydrogel. The hydrogel is thermo-responsive at a physiological temperature and changes after application to a more solid state due to body temperatures. The composition includes one or more treatment agents to be released over time as the composition degrades. The composition can be varied to modify the structure and/or release of the treatment agent. The degradable microcapsules include one or more of magnesium hydroxide (Mg(OH)2), bovine serum albumin (BSA), polyethylene glycol (PEG), and sucrose to improve release duration.

Abstract: Systems and method that relate to improving levels, functions, and resistances related to chronic conditions by using lysine-based supplements are described. For example, a method of monitoring an analyte level may include administering a supplement that may include lysine, zinc, and vitamin C to a user. The method may also include monitoring an analyte level in a bio-sample before and after the supplement is administered.

Abstract: The present invention relates generally method of treating or alleviating cognitive impairment by administering an abuse-deterrent formulation containing dextroamphetamine sulfate.

Abstract: The present disclosure relates to methods or dosing regimens comprising a proteasome inhibitor of formula (I), or a pharmaceutically acceptable salt thereof, for treating cancer, or preventing cancer recurrence or progression; wherein ring A, Z1 and Z2 are as defined herein.

Abstract: A manufacturing method of an ascorbic acid dispersion material includes a heating step of adding an ascorbic acid into a solvent including one or more selected from the group consisting of glycerin, diglycerin, polyglycerin represented by a following formula, and propylene glycol, and heating the ascorbic acid to a predetermined temperature to dissolve the ascorbic acid; a cooling step of cooling a solution with the ascorbic acid dissolved therein at a cooling rate of 5 to 20° C./min until a temperature of the solution reaches 35 to 50° C. to remove heat from the solution; and a growth step of storing the solution after completion of the cooling step at 27 to 38° C. for a predetermined period to promote crystal growth so that the ascorbic acid crystal has a flat plate shape, a thickness of 0.05 to 3 ?m, and an average particle diameter of 50 to 100 ?m.

Abstract: This invention related to manufactured microbubbles, as well as methods of using manufactured microbubbles, for example, in medicinal applications. The invention pertains to the physical structure and materials of the microbubbles, as well as to methods for manufacturing microbubbles, methods for targeting microbubbles for specific medicinal applications, and methods for delivering microbubbles in medical treatment.

Abstract: Low foaming, highly acidic peroxycarboxylic acid sanitizing compositions are disclosed as having both improved antimicrobial efficacy in comparison to conventional peroxyoctanoic acid and peroxyacetic acid compositions for sanitizing applications. The compositions include a combination of a low-foaming surfactant and an aluminum sulfate (or other metal salt) defoaming agent that is compatible with the highly acidic peroxycarboxylic acid sanitizing compositions. In particular, the sanitizing peroxycarboxylic acid compositions are also low odor and low/no VOC dual functioning acid wash and sanitizing compositions.

Abstract: Provided herein are compositions, methods of making the same, and methods for targeted delivery of therapeutic agents for modifying expression and function of target genes, e.g. proteins involved in lipid and cholesterol metabolism such as PCSK9. Further provided herein are compositions and methods of treating conditions related to coronary disease.

Abstract: Compounds including vitamins and aspirin are disclosed. The compounds are provided in dosage form and preferably include selected amounts of folic acid, vitamin D, calcium, vitamin C, thiamine, and riboflavin with the aspirin. A protective coating is preferably provided between the aspirin and the other vitamin and mineral constituents. The dosages are effective in the treatment and prevention of pre-natal conditions.

Abstract: The present invention is for sanitizing compositions for sanitizing surfaces which may contact food. The composition may be provided in liquid form, and may include a quaternary amine, one or more surfactant, a fragrance, and water. At least 90% by weight of the fragrance comprises fragrance components that meet Class I qualifications of the Cramer classification system. All other components of the composition (e.g., the quaternary amine, the surfactants, water, and any optional components) meet the EPA guidelines under CFR 180.940(a). Since the composition only includes components that meet the EPA guidelines under CFR 180.940(a) (reflecting a presumption of low toxicity), and at least 90% of the fragrance itself (e.g., in the case of mixtures of fragrance components) meets the Cramer Class I qualifications, the composition is safe for application to surfaces that come in contact with food, where there is a heightened probability that traces of the composition will be ingested.